Vascular-Targeted Therapies in Oncology

Copyright © 2006 John Wiley & Sons, Ltd

Vascular-Targeted Therapies in Oncology

Editor(s): Dietmar W. Siemann

Published Online: 31 MAY 2006

Print ISBN: 9780470012949

Online ISBN: 9780470035436

DOI: 10.1002/0470035439

About this Book

Product Information

About The Product

Vascular-Targeted Therapies in Oncology provides an interesting insight to the current status and future potential of vascular-disrupting approaches in cancer management. Emphasis is placed on target development, preclinical assessment, and the use of such targeted approaches in combination with conventional treatment regimens and the current clinical status of these therapies.

Table of contents

    1. You have free access to this content
      Front Matter (pages i–xvii)

    2. You have free access to this content
      Colour Plates (pages c1–c8)

    3. Chapter 1

      Tumor Vasculature: a Target for Anticancer Therapies (pages 1–8)

      Dietmar W. Siemann

    4. Chapter 2

      Abnormal Microvasculature and Defective Microcirculatory Function in Solid Tumors (pages 9–29)

      Peter Vaupel

    5. Chapter 3

      The Role of Microvasculature in Metastasis Formation (pages 31–62)

      Oliver Stoeltzing and Lee M. Ellis

    6. Chapter 4

      Development of Agents that Selectively Disrupt Tumor Vasculature: A Historical Perspective (pages 63–80)

      David J. Chaplin and Sally A. Hill

    7. Chapter 5

      Morphologic Manifestations of Vascular-disrupting Agents in Preclinical Models (pages 81–94)

      Mumtaz V. Rojiani and Amyn M. Rojiani

    8. Chapter 6

      Molecular Recognition of the Colchicine Binding Site as a Design Paradigm for the Discovery and Development of Vascular Disrupting Agents (pages 95–121)

      Kevin G. Pinney

    9. Chapter 7

      Combined Modality Approaches Using Vasculature-disrupting Agents (pages 123–136)

      Wenyin Shi, Michael R. Horsman and Dietmar W. Siemann

    10. Chapter 8

      Vasculature-targeting Therapies and Hyperthermia (pages 137–157)

      Michael R. Horsman and Rumi Murata

    11. Chapter 9

      Flavones and Xanthenones as Vascular-disrupting Agents (pages 159–178)

      Bronwyn G. Siim and Bruce C. Baguley

    12. Chapter 10

      Targeting Inside-Out Phospholipids on Tumor Blood Vessels in Pancreatic Cancer (pages 179–194)

      Adam W. Beck, Rolf A. Brekken and Philip E. Thorpe

    13. Chapter 11

      Cadherin Antagonists as Vasculature-targeting Agents (pages 195–204)

      Orest W. Blaschuk and Tracey M. Rowlands

    14. Chapter 12

      Alphastatin: a Pluripotent Inhibitor of Activated Endothelial Cells (pages 205–220)

      Carolyn A. Staton and Claire E. Lewis

    15. Chapter 13

      Cationic Lipid Complexes to Target Tumor Endothelium (pages 221–245)

      Uwe Michaelis and Michael Teifel

    16. Chapter 14

      Development of Vasculature-targeted Cancer Gene Therapy (pages 247–259)

      Graeme J. Dougherty, Peter D. Davis and Shona T. Dougherty

    17. Chapter 15

      Vasculature-disrupting Strategies Combined with Bacterial Spores Targeting Hypoxic Regions of Solid Tumors (pages 261–276)

      G-One Ahn and J. Martin Brown

    18. Chapter 16

      Imaging the Effects of Vasculature-targeting Agents (pages 277–304)

      Susan M. Galbraith

    19. Chapter 17

      Clinical Progress in Tumor Vasculature-disrupting Therapies (pages 305–322)

      Andrew M. Gaya and Gordon J. S. Rustin

    20. Chapter 18

      Use of Vasculature-disrupting Agents in Non-Oncology Indications (pages 323–340)

      Joseph C. Randall and Scott L. Young

    21. You have free access to this content
      Index (pages 341–350)

SEARCH